Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol(CCCG-LR-B-ALL) | recruiting | Phase 2 / Phase 3 | 3,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT06952478 | A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | recruiting | Phase 3 | 486 | CelltrionINDUSTRY |
| 1 |
| Aug 15, 2025 |
| clinicaltrials |
| NCT06464991 | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)(FUMANBA-03) | recruiting | Phase 3 | 240 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT03937544 | Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL | recruiting | Phase 2 / Phase 3 | 10 | National University of MalaysiaOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT04513639 | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | recruiting | Phase 2 / Phase 3 | 176 | Oslo University HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06879379 | KPD Consolidation After ASCT in NDMM Patients | recruiting | Phase 2 / Phase 3 | 202 | Peking University People's HospitalOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05595447 | Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 / Phase 3 | 20 | Hospital Regional de Alta Especialidad del BajioOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06170489 | A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) | recruiting | Phase 3 | 185 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06361329 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | recruiting | Phase 3 | 81 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06830421 | Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients(PRIMA-CNS) | recruiting | Phase 3 | 340 | University Hospital FreiburgOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | recruiting | Phase 3 | 476 | InnoCare Pharma Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06561854 | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone(FREEDOM) | recruiting | Phase 3 | 318 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05665140 | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients(ELIAS) | recruiting | Phase 2 / Phase 3 | 100 | University Hopsital Schleswig Holstein Campus LübeckOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06588413 | Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan(FONDO-LOW) | recruiting | Phase 3 | 172 | Augusta UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)(HL-Russia-1) | recruiting | Phase 3 | 300 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaOTHER | 2 | Sep 27, 2024 | clinicaltrials |
| NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia(BBClean) | recruiting | Phase 2 / Phase 3 | 90 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)(HOVON174MM) | recruiting | Phase 3 | 599 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | recruiting | Phase 3 | 100 | Ruijin HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06520176 | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 244 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | recruiting | Phase 3 | 78 | Ruijin HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | recruiting | Phase 3 | 146 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04442412 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy(FIL_PREVID) | recruiting | Phase 3 | 430 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT04670029 | Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line(PHARAOM) | recruiting | Phase 3 | 186 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2025source: clinicaltrials